UK medtech firm in record-breaking US clinical trial

A new cardiac diagnostic device aimed at helping physicians rule out active ischemia in patients presenting to the emergency department (ED) with chest pain is being trialled at five major research facilities in the United States.

The trial will take place across the Mayo Clinic, Rochester, MN; Baylor University, Houston, TX; Vanderbilt University, Nashville, TN; University of Cincinnati, OH; and Wake Forest University, Winston-Salem, NC).

The device, developed by Creavo Medical Technologies, a UK-based medical device company, is a mobile medical magnetometer which can be used at a patient’s bedside to measure and report electromagnetic fluctuations caused by heart activity.

Approximately 720 patients will be enrolled throughout the trial, which is the largest magnetocardiography (MCG) trial ever to take place in the United States and is scheduled to be completed by mid-2019.

Gregory J. Fermann, MD, Professor, Executive Vice Chairman and Director of the Clinical Trials Centre at the University of Cincinnati said: “The ability to quickly risk stratify and safely discharge emergency department patients presenting with symptoms consistent with chest pain of cardiac origin is critically important to the overall flow of patients through crowded Emergency Departments. This device has the potential to become an essential tool in the rapid evaluation of these patients.”